News from abbvie A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Feb 26, 2015, 16:48 ET

AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting

 AbbVie (NYSE: ABBV) today announced that 15 abstracts of studies in its neuroscience and oncology development programs have been accepted for...

Feb 26, 2015, 08:00 ET

AbbVie Launches SigueElGuion.com to Educate Spanish-Speaking Americans about Hypothyroidism and the Importance of Dialogue between Patient and Healthcare Professional

 To further awareness about the importance of diagnosing and treating hypothyroidism, a thyroid condition that affects millions of...

Feb 26, 2015, 08:00 ET

AbbVie lanza SigueElGuion.com para instruir a los estadounidenses de habla hispana acerca del hipotiroidismo y la importancia del diálogo entre el paciente y el profesional de la salud

Para aumentar la concientización sobre la importancia de diagnosticar y tratar el hipotiroidismo, una afección de la tiroides que afecta...

Feb 25, 2015, 08:22 ET

AbbVie to Present at Cowen 35th Annual Health Care Conference

AbbVie (NYSE: ABBV) will participate in the Cowen 35th Annual Health Care Conference on Wednesday, March 4, 2015. Bill Chase, executive vice...

Feb 19, 2015, 12:12 ET

AbbVie Increases Quarterly Dividend

 The board of directors of AbbVie Inc. (NYSE: ABBV) increased the company's quarterly cash dividend by 4 percent from $0.49 per share to $0.51...

Feb 11, 2015, 22:04 ET

AbbVie Submits New Drug Application in Japan for its Investigational, All-Oral, Treatment for Chronic Hepatitis C

 AbbVie (NYSE: ABBV) submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare (MHLW) seeking approval for...

Jan 30, 2015, 18:00 ET

AbbVie Announces Top-line Results from Phase 3 Study of All-Oral Treatment for Hepatitis C in Japan

- 95 percent SVR12 rate achieved in Japanese patients new to therapy with genotype 1b chronic hepatitis C virus infection without cirrhosis and...

Jan 30, 2015, 07:47 ET

AbbVie Reports Fourth-Quarter and Full-Year 2014 Financial Results

 AbbVie (NYSE:ABBV) today announced financial results for the fourth quarter and full year ended Dec. 31, 2014. "AbbVie delivered exceptional...

Jan 16, 2015, 10:08 ET

AbbVie Announces U.S. FDA Approval of DUOPA™ (carbidopa and levodopa) Enteral Suspension for the Treatment of Motor Fluctuations in Patients with Advanced Parkinson's Disease

The U.S. Food and Drug Administration (FDA) has approved AbbVie's (NYSE: ABBV) DUOPA™ (carbidopa and levodopa) enteral suspension for the...

Jan 16, 2015, 07:00 ET

AbbVie to Host Fourth-Quarter and Full-Year 2014 Earnings Conference Call

 AbbVie (NYSE: ABBV) will announce its fourth-quarter and full-year 2014 financial results on Friday, Jan. 30, 2015, before the market...

Jan 16, 2015, 02:00 ET

European Commission Grants Marketing Authorizations for AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for the Treatment of Chronic Hepatitis C

 AbbVie (NYSE: ABBV) announced that the European Commission has granted marketing authorizations for its all-oral, short-course,...

Jan 12, 2015, 08:00 ET

AbbVie Announces U.S. FDA Approval of DUOPA™ (carbidopa and levodopa) Enteral Suspension for the Treatment of Motor Fluctuations in Patients with Advanced Parkinson's Disease

 The U.S. Food and Drug Administration (FDA) has approved AbbVie's (NYSE: ABBV) DUOPA™ (carbidopa and levodopa) enteral suspension for...

Jan 08, 2015, 16:07 ET

AbbVie Issues Strong Outlook for 2015

 AbbVie (NYSE: ABBV) today issued earnings-per-share guidance for the full-year 2015.  AbbVie expects diluted earnings per share of...

Jan 08, 2015, 08:00 ET

AbbVie Announces Positive Top-Line Results From Phase 3 Study of Investigational Medicine Elagolix in Patients with Endometriosis

 AbbVie (NYSE: ABBV), in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), announced positive top-line results from the first of...

Dec 30, 2014, 16:05 ET

AbbVie to Present at 33rd Annual J.P. Morgan Healthcare Conference

AbbVie (NYSE: ABBV) will participate in the 33rd Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 14, 2015. Bill Chase, executive vice...

Dec 23, 2014, 08:00 ET

AbbVie to Present at Goldman Sachs Healthcare CEOs Unscripted Conference

 AbbVie (NYSE: ABBV) will participate in the Goldman Sachs Healthcare CEOs Unscripted Conference on Tuesday, Jan. 6, 2015. Richard A. Gonzalez,...

Dec 23, 2014, 07:00 ET

AbbVie Receives Health Canada Approval of HOLKIRA™ PAK for the Treatment of Chronic Genotype 1 Hepatitis C

- New all-oral, short-course (12 weeks), interferon-free treatment available in Canada for genotype 1 hepatitis C patients - In Phase 3...

Dec 19, 2014, 17:45 ET

AbbVie Receives U.S. FDA Approval of VIEKIRA PAK™ (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) for the Treatment of Chronic Genotype 1 Hepatitis C

 The U.S. Food and Drug Administration (FDA) has approved AbbVie's (NYSE:ABBV) VIEKIRA PAK™, an all-oral, interferon-free treatment, with...

Dec 07, 2014, 20:15 ET

AbbVie Presents Results from Phase 2 Study of Investigational Compound Venetoclax (ABT-199/GDC-0199) in Acute Myelogenous Leukemia at the 56th American Society of Hematology Annual Meeting

 AbbVie (NYSE: ABBV) presented during an oral presentation at the American Society of Hematology's 56th Annual Meeting new results from a Phase...